4 completed, 1 recruiting, 1 terminated. 4 Phase 3, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow Generalized Lipodystrophy: new trials by email Literature Review of Generalized Lipodystrophy trials Research Report on Generalized Lipodystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy Mibavademab, Placebo - Generalized Lipodystrophy | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 28 | 2026-03-13 | 2026-10-23 |
| Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy Metreleptin - Generalized Lipodystrophy | Phase 3 | Terminated | Amryt Pharma | 1 | 2025-05-23 | 2026-07-22 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy Placebo, Low-Dose REGN4461, High-dose REGN4461 - Generalized Lipodystrophy | Phase 2 | Completed | Regeneron Pharmaceuticals | 16 | 2020-01-07 | 2026-06-15 |
| Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy Metreleptin - Generalized Lipodystrophy | Phase 4 | Completed | Aegerion Pharmaceuticals, Inc. | 11 | 2018-11-14 | 2025-11-26 |
| Trial of Leptin Replacement Therapy in Patients With Lipodystrophy Leptin, Placebo - Hypoleptinemia, Generalized Lipodystrophy | Phase 2 / Phase 3 | Completed | University of Texas Southwestern Medical Center | 25 | 2006-04-01 | 2024-03-27 |
Lipodystrophy, Congenital Generalized (6) · Insulin Resistance (2) · Lipodystrophy (2) · Lipodystrophy, Familial Partial (2) · Diabetes Mellitus (1) · Hypertriglyceridemia (1) · Lipodystrophy, Partial, Acquired (1) · Obesity, Morbid (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Lipid Metabolism Disorders (6) · Lipid Metabolism, Inborn Errors (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Nutritional and Metabolic Diseases (6) · Skin Diseases (6) · Skin Diseases, Metabolic (6) · Skin and Connective Tissue Diseases (6) · Lipodystrophy (4) · Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Laminopathies (2) · Body Weight (1)
metreleptin (2) · Leptin (1) · recombinant methionyl human leptin (1)
Regeneron Pharmaceuticals (3) · Aegerion Pharmaceuticals, Inc. (1) · Amryt Pharma (1) · University of Texas Southwestern Medical Center (1)
United States (5) · France (2) · Belgium (1) · Brazil (1) · Germany (1) · Italy (1) · Peru (1) · Russia (1) · Turkey (Türkiye) (1)
Abhimanyu Garg, MD (1) · Janet Boylan (1)
2019 (1)